A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  • STATUS
    Not Recruiting
  • End date
    Feb 1, 2026
  • participants needed
    2600
  • sponsor
    Eli Lilly and Company
Updated on 26 January 2021
Investigator
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Primary Contact
GCM Medical Group PSC (2.3 mi away) Contact
+605 other location
body mass index
tumor necrosis factor
DMARD
tumor necrosis factor alpha
tumour necrosis
baricitinib
antirheumatics

Summary

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Details
Condition Rheumatoid Arthritis, Rheumatoid Arthritis (Pediatric)
Treatment Baricitinib, TNF Inhibitor
Clinical Study IdentifierNCT03915964
SponsorEli Lilly and Company
Last Modified on26 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note